<p>(<b>A</b>) The E106 Fab epitope on DENV-1 E DIII is comprised of residues in the A-strand (K307 and K310), the end of the B-strand (K325 and Y326), and the connecting BC (E327, T329, and D330) and DE (K361 and E362) loops. The immunoglobulin-like DIII is shown in blue (epitope regions in magenta), with the E106 heavy chain in green and light chain in cyan. (<b>B</b>) Heavy chain residue W98 binds in a deep pocket contributed by the aliphatic groups of side chain DENV-1 E DIII residues K307, K325, and E327 and main chain of Y326, in stereo (top panel). The electron density map is contoured at 1.1σ. Ball and stick representation of the molecular interactions involving T329 (the residue that escapes neutralization <a href="http://www.plospa...
<p>(A) Overview of DENV3 RdRp bound to compound <b>29</b> (boxed), displayed as ribbons with the pal...
<p>(<b>A</b>) Residues from the combining sites of 4E10 and GEPs, superimposed based on bound-state ...
<div><p>We previously developed a panel of neutralizing monoclonal antibodies against Dengue virus (...
<p>A ribbon diagram of the crystal structure of (<b>A</b>) E111 scFv in complex with DENV-1 strain 1...
<p>(<b>A</b>) The E106 epitope is highlighted in magenta on a DENV-1 model of the DENV-2 cryo-electr...
<p><b>A.</b> the structure of the 2A10G6 epitope in the crystal structure of DENV2 E protein. Residu...
<p>The flavivirus E protein contains three distinct domains (DI–III) and forms antiparallel dimers o...
<p>The atomic structures of the (<b>A</b>) mature (PDB 1K4R), (<b>B</b>) immature (PDB 3C6D), and (<...
<p>The structural interface of DENV-1 DIII-E106 Fab (described by the surface area of antibody, Ab<i...
<p>The rings represent the area mapped to be the footprint of each mAb on the surface of ED3. The 4E...
<p>(A) Crystal structure of the DENV-2 E protein dimer <a href="http://www.plosone.org/article/info:...
<p>A. Molecular interactions of E-DENV1 protein (shown in rainbow color cartoon) are shown with the ...
<p>Epitope residues of mAbs against DENV1 (A) and DENV2 (B). Epitope residues are highlighted with d...
<p>(<b>A</b>) <i>3D organization of the DENV NS1 dimer and hexamer</i>. The left panel shows a <i>ri...
<p>(A) Open state as observed in the ligand-free conformation in the crystal structure 2FOM [<a href...
<p>(A) Overview of DENV3 RdRp bound to compound <b>29</b> (boxed), displayed as ribbons with the pal...
<p>(<b>A</b>) Residues from the combining sites of 4E10 and GEPs, superimposed based on bound-state ...
<div><p>We previously developed a panel of neutralizing monoclonal antibodies against Dengue virus (...
<p>A ribbon diagram of the crystal structure of (<b>A</b>) E111 scFv in complex with DENV-1 strain 1...
<p>(<b>A</b>) The E106 epitope is highlighted in magenta on a DENV-1 model of the DENV-2 cryo-electr...
<p><b>A.</b> the structure of the 2A10G6 epitope in the crystal structure of DENV2 E protein. Residu...
<p>The flavivirus E protein contains three distinct domains (DI–III) and forms antiparallel dimers o...
<p>The atomic structures of the (<b>A</b>) mature (PDB 1K4R), (<b>B</b>) immature (PDB 3C6D), and (<...
<p>The structural interface of DENV-1 DIII-E106 Fab (described by the surface area of antibody, Ab<i...
<p>The rings represent the area mapped to be the footprint of each mAb on the surface of ED3. The 4E...
<p>(A) Crystal structure of the DENV-2 E protein dimer <a href="http://www.plosone.org/article/info:...
<p>A. Molecular interactions of E-DENV1 protein (shown in rainbow color cartoon) are shown with the ...
<p>Epitope residues of mAbs against DENV1 (A) and DENV2 (B). Epitope residues are highlighted with d...
<p>(<b>A</b>) <i>3D organization of the DENV NS1 dimer and hexamer</i>. The left panel shows a <i>ri...
<p>(A) Open state as observed in the ligand-free conformation in the crystal structure 2FOM [<a href...
<p>(A) Overview of DENV3 RdRp bound to compound <b>29</b> (boxed), displayed as ribbons with the pal...
<p>(<b>A</b>) Residues from the combining sites of 4E10 and GEPs, superimposed based on bound-state ...
<div><p>We previously developed a panel of neutralizing monoclonal antibodies against Dengue virus (...